Tables--Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 1. Table 6

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 6. Summary of Tumor Response in Studies of First-line Treatment With EGFR-TK Inhibitors (Single Agent) for Advanced NSCLC

Study ID	Diagnosis (no. of patients) [agent]	Sub-groups	N	Survival from start of treatment		Tumor response
Study ID	Diagnosis (no. of patients) [agent]	Sub-groups	N	Median (months)	1-year (%)	% CR	% PR	% SD	% DP	% NE
All NSCLC
Niho, et al., 2004¹¹	NSCLC (37) [Gefitinib]	- -	37	- -	- -	0	27	- -	- -	- -
Giaccone, et al., 2005¹²	NSCLC (53) [Erlotinib]	- -	53	- -	- -	2	23	30	32	13
Kasahara, et al., 2005¹³	NSCLC (30) [Gefitinib]	- -	30	10	43.3	0	33	30	37	- -
Suzuki, et al., 2005¹⁴	NSCLC (34) [Gefitinib]	- -	34	- -	- -	0	26	- -	- -	- -
Reck, et al., 2005¹⁵	NSCLC (58) [Gefitinib]	- -	58	- -	- -	2	3	40	48	- -
D'Addario, et al., 2005¹⁶	NSCLC (63) [Gefitinib]	- -	63	10	- -	2	8	27	57	6
Lee, et al., 2005¹⁷	NSCLC (55) [Gefitinib]	- -	55	Not reached	76.1	4	57	11	28	- -
BAC
West, et al., 2004¹⁸	NSCLC (138) [Gefitinib]	Chemo-naive Previous treatment (26%)	67 21	12 10	~50 ~50	6 0	15 10	- -	- -	- -
Kris, et al., 2004¹⁹	NSCLC (69) [Erlotinib]	- -	59	Median not reached	58	- -	25 (15-38)	- -	- -	- -
Elderly
Jackman, et al., 2005²¹	NSCLC (58) [Erlotinib]	- -	66	11	- -	0	12	48	39	- -
Poor PS
Dickson, et al., 2004²²	NSCLC (25) [Gefitinib]	- -	18	Median not reached	Follow up < 1 year	- -	- -	61	39	- -

Abbreviations: BAC = bronchoalveolar carcinoma; CR = complete response; DP = disease progression; EGFR-TK = epidermal growth factor receptor tyrosine kinase; NE = not evaluable; NSCLC = non-small cell lung cancer; no. = number; PR = partial response; SD = stable disease.

Return to Document

The information on this page is archived and provided for reference purposes only.